Predictive biological markers for response of invasive breast cancer to anthracycline / cyclophosphamide-based primary (radio-) chemotherapy

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4615-4621

  Prisack, Hans Bernd ^a   Karreman, Christiaan ^a   Modlich, Olga ^a   Audretsch, Werner ^b   Danae, Mahmoud ^a   Rezai, Mahadi ^c   Bojar, Hans ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Breast Center Düsseldorf Luisenkrankenhaus   (Germany)

^c Luisenkrankenhaus Düsseldorf ^*  (Germany)

Author keywords

Bcl 2; EGF R; ER ; Her 2 neu; p53; PgR; Proliferation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27344435204     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kuerer HM, Newman LA, Smith TL et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
2. Schwartz GF and Hortobagyi GN: Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 100: 2512-2532, 2004.
3. Burcombe RJ, Makris A, Richman PI et al: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92: 147-155, 2005.
4. Ross JS, Fletcher JA, Bloom KJ et al: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Review. Mol Cell Proteomics 3: 379-398, 2004.
5. Thames HD, Petersen C, Petersen S, Nieder C and Baumann M: Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. Strahlenther Onkol 178: 411-421, 2002.
6. Daidone MG, Luisi A, Veneroni S, Benini E and Silvestrini R: Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Rev Endocr Relat Cancer 6: 61-68, 1999.
7. Ayers M, Symmans WF, Stec J et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293, 2004.
8. Altman DG and Lyman GH: Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303, 1998.
9. Hanley JA and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
10. Bicciato S, Luchini A and Di Bello C: Marker identification and classification of cancer types using gene expression data and SIMCA. Methods Inf Med 43: 4-8, 2004.
11. Wikstrom P, Wikstrom P, Lissbrant IF, Bergh A, Damber JE and Stattin P: Evaluation of prognostic factors in prostate cancer with partial least squares analysis. Scand J Urol Nephrol 34: 252-256, 2000.
12. Aryus B, Audretsch W, Gogolin F et al: Remission rates following preoperative chemotherapy and radiation therapy in patients with breast cancer. Strahlenther Onkol 176: 411-415, 2000.
13. Bottini A, Berruti M, Brizzi P et al: Single agent epirubicin versus the combination epirubicin plus tamoxifen as primary chemotherapy in breast cancer patients. Proc Am Soc Clin Oncol 22: 21 (abstr 80), 2003.
14. Colleoni M, Viale G, Zahrieh D et al: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10: 6622-6628, 2004.
15. Ring AE, Smith IE, Ashley S, Fulford LG and Lakhani SR: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91: 2012-2017, 2004.
16. Bottini A, Berruti A, Bersiga et al: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758, 2000.
17. Ogston KN, Miller ID, Schofield AC et al: Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res Treat 86: 181-189, 2004.
18. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S and van de Vijver MJ: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88: 406-412, 2003.
19. Petit T, Wilt M, Velten M et al: Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40: 205-211, 2004.
20. Vincent-Salomon A, Carton M, Freneaux P et al: ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 36: 586-591, 2000.
21. Rozan S, Vincent-Salomon A, Zafrani B et al: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27-33, 1998.
22. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J and Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8: 3454-3460, 2002.
23. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J and Hachitanda Y: Prognostic significance of the combination of biological parameters in breast cancer. Surg Today 33: 151-154, 2003.
24. Perez-Enciso M and Tenenhaus M: Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. Hum Genet 112: 581-592, 2003.
25. Wilkstroem P, Wilkstroem P, Lissbrant IF, Bergh A, Damber JE and Stattin P: Evaluation of prognostic factors in prostate cancer with partial least squares analysis. Scand J Urol Nephrol 34: 252-256, 2000.